|
Latest Reports
|
| Date |
Description |
Country |
Analyst |
Download |
|
|
| 08-Feb-2024 |
Lupin - Spiriva as well as pipeline benefits already priced in; SELL with TP Rs 1300: |
India |
Surya Patra |
 |
| 07-Aug-2023 |
Lupin Trades ahead of visible triggers; Downgrades to SELL with TP of Rs 850 |
India |
Surya Patra |
|
| 12-May-2023 |
Lupin - All eyes on gSpiriva launch; Maintain Neutral rating with TP Rs 720 |
India |
Surya Patra |
|
| 12-Feb-2023 |
Lupin - Deferred launch of gSpiriva hurts FY23 earnings; Maintain Neutral with lowered TP Rs 640 |
India |
Surya Patra |
|
| 10-Nov-2022 |
Lupin - Recovery in Q2, Hopes pinned on gSpiriva; Maintain NEUTRAL with TP of Rs 670 |
India |
Surya Patra |
|
| 05-Aug-2022 |
Lupin - Hit the bottom in Q1, Expects profitable recovery from Q2; Maintain Neutral with lowered TP Rs 650 |
India |
Surya Patra |
|
| 20-May-2022 |
Lupin - Earning challenges to continue in H1: Maintain NEUTRAL with lowered TP Rs 710 |
India |
Surya Patra |
|
| 07-Feb-2022 |
Lupin - Albuterol ramp up in the US failed to improve earnings; Remain Neutral with TP Rs 1000 |
India |
Surya Patra |
|
| 29-Oct-2021 |
Lupin - All eyes on gSpiriva for earnings improvement; Maintain Neutral with lowered TP Rs 1000 |
India |
Surya Patra |
|
| 12-Aug-2021 |
Lupin - Inhalation drugs will drive sequential recovery; Maintain Neutral with TP Rs 1100 |
India |
Surya Patra |
|
| 13-May-2021 |
Lupin - Visible triggers baked in price; Downgrade to Neutral with TP of Rs 1200 |
India |
Surya Patra |
|
| 31-Jan-2021 |
Lupin (LPC IN) - Recovery in operating performance is well in price; Maintain NEUTRAL with TP Rs 1000 |
India |
Surya Patra |
|
| 06-Nov-2020 |
Lupin - Likely to see gradual recovery in profitability; Maintain Neutral with TP Rs 90 |
India |
Surya Patra |
|
| 10-Aug-2020 |
Lupin (LPC IN) - Optimism hinges on specialty drug launches; Maintain Neutral with TP Rs 780 |
India |
Surya Patra |
|
| 31-May-2020 |
Lupin (LPC IN) - Cleansing of BS adds more value to Equity; Maintain Neutral with raised TP Rs 800 |
India |
Surya Patra |
|
| 07-Feb-2020 |
Lupin (LPC IN) : Mounting operational challenges concern us |
India |
Surya Patra |
|
| 13-Nov-2019 |
Lupin Ltd - Q2FY20 - Kyowa divestment is EPS accretive but not meaningful; Retain SELL with TP Rs 650 |
India |
Surya Patra |
|
| 07-Nov-2019 |
Lupin (LPC IN): Earning challenges persist (SELl Maintain TP Rs 640) |
India |
Surya Patra |
|
| 08-Aug-2019 |
Lupin (LPC IN) - Mired in growth as well as operational challenges; Reiterate SELL with TP Rs 640 |
India |
Surya Patra |
|
| 16-May-2019 |
Lupin (LPC IN) - Mired under operational and regulatory challenges; SELL with TP of Rs 660 |
India |
Surya Patra |
|
| 17-Mar-2019 |
Lupin (LPC IN) - Mounting regulatory issues raise growth/valuation concerns; Reiterate SELL with TP of Rs 700 |
India |
Surya Patra |
|
| 07-Feb-2019 |
Lupin (LPC IN) - Hopeful about US growth, but profitability trials persist; SELL with TP of Rs 700 |
India |
Surya Patra |
|
| 24-Dec-2018 |
Lupin -Deal with Abbvie is a strategic but futuristic; Re-iterate SELL |
India |
Surya Patra |
|
| 10-Aug-2018 |
Lupin (LPC IN) - Weakness in key markets & higher cost concern: Downgrade to SELL |
India |
Surya Patra |
|
| 16-May-2018 |
Lupin (LPC IN) - US business continues to remain sluggish; NEUTRAL with TP of Rs 820 |
India |
Surya Patra |
|
|
|